Conditions: Choroidal Neovascularization Age-Related Maculopathy
Allocation: RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 243
Healthy volunteers: no

Brief summary:
The study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with Anti-VEGF treatment vs. Anti-VEGF alone (with sham dexamethasone injection) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

Detailed description:

Arms:
arm 1: Intravitreal injection of dexamethasone 700 µg at Day 1; ranibizumab 500 µg at Day -30 and Day 7-14. arm 2: Sham injection at Day 1; ranibizumab 500 µg at day -30 and Day 7-14.

Interventions: intervention 1: dexamethasone intervention 2: ranibizumab intervention 3: sham
Intervention descriptions: intervention 1: Intravitreal injection of dexamethasone 700 µg at Day 1. intervention 2: Ranibizumab 500 µg at day -30 and Day 7-14. intervention 3: Sham needle-less injection administered in the study eye at Day 1.

Protocol document: